Table 2. Clinical and pathological characteristics for CYR61 expression in FFPE samples (115 bladder urothelium carcinoma).
| Characteristics | Low expression (n=68), n (%) | High expression (n=47), n (%) | P valuea |
|---|---|---|---|
| Age, years | 0.357b | ||
| Mean ± SD | 59.99±12.07 | 62.00±10.54 | |
| Median [range] | 61.0 [32–82] | 62.0 [34–79] | |
| Sex | 0.719 | ||
| Male | 54 (60.0) | 36 (40.0) | |
| Female | 14 (56.0) | 11 (44.0) | |
| Alcohol consumption | 0.186 | ||
| Yes | 6 (42.9) | 8 (57.1) | |
| No | 62 (61.4) | 39 (38.6) | |
| Smoking history | 0.684 | ||
| Yes | 35 (51.5) | 26 (48.5) | |
| No | 33 (55.3) | 21 (44.7) | |
| Tumor stage (n=115) | <0.001* | ||
| Non-invasive (n=59) | 48 (82.8) | 10 (17.2) | |
| Ta | 5 | 0 | |
| T1 | 44 | 10 | |
| Invasive (n=56) | 20 (35.1) | 37 (64.9) | |
| T2 | 17 | 20 | |
| T3 | 2 | 14 | |
| T4 | 0 | 3 | |
| Tumor grade | 0.120 | ||
| Low | 30 (68.2) | 14 (31.8) | |
| High | 38 (53.5) | 33 (46.5) | |
| Peduncle | 0.226 | ||
| Yes | 27 (65.9) | 14 (34.1) | |
| No | 39 (54.2) | 33 (45.8) | |
| Recurrence | 0.645c | ||
| Yes | 36 (63.2) | 21 (36.8) | |
| No | 30 (58.8) | 21 (41.2) |
*, P<0.05 indicated statistical significance; a, χ2-test; b, Student’s t-test; c, 7 of 115 patients were lost to follow-up. CYR61, cysteine-rich angiogenic inducer 61; FFPE, formalin-fixed, paraffin-embedded; SD, standard deviation.